Literature DB >> 28185319

Gabapentenoids in pain management in urological chronic pelvic pain syndrome: Gabapentin or pregabalin?

Mayank Mohan Agarwal1, Mudelin Elsi Sy1.   

Abstract

AIMS: To compare efficacy of gabapentin and pregabalin in patients with urological chronic pelvic-pain syndrome (UCPPS).
METHODS: Design-retrospective, setting-urology outpatient services of a secondary-care private hospital, inclusion criteria-men 18-50 years, presenting with pelvic pain (lower abdomen, groin, scrotum, perineum, low-back, hip) with or without lower urinary tract symptoms for at least 3 months duration. Hospital database was searched using keywords for neuropathic pain (ICD9-729.2, 719.45) and prostatitis (ICD9-601.1, 601.9). Clinical data were retrieved from patient-records, laboratory and radiology data, and analyzed using SPSS-19 statistical software.
RESULTS: Between Mar 2013 and Oct 2015, data of consecutive 119 patients fulfilling the above criteria was analyzed. Median age of patients was 35 years (IQR 29-43) and median duration of symptoms 12 months (IQR 6-24 months). Before treatment median VAS (0-10) pain score was 5 (IQR 4-6). Gabapentin was significantly more effective in controlling pain compared to pregabalin. Three fourth of patients on gabapentin alone (47/62) reported at least 50% improvement in pain compared to only 40% on pregabalin alone (12/30) (P = 0.0012; χ2  = 9.765. NNT 2.9, 95%CI 1.8-6.5). Twenty patients who were initially put on pregabalin had to switch to gabapentin for lack of efficacy. Forty four percent of patients on pregabalin required amitriptyline (24/54) compared to only 13.6% of those on gabapentin (10/72) required the same (P value of difference 0.0001; χ2  = 14.622. NNT 4, CI 95% 2.2-6.6).
CONCLUSIONS: Gabapentin may be more effective than pregabalin in UCPPS.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  gabapentin; pelvic pain; pregabalin; prostatitis

Mesh:

Substances:

Year:  2017        PMID: 28185319     DOI: 10.1002/nau.23225

Source DB:  PubMed          Journal:  Neurourol Urodyn        ISSN: 0733-2467            Impact factor:   2.696


  8 in total

1.  Evaluation and Management of Chronic Scrotal Content Pain-A Common Yet Poorly Understood Condition.

Authors:  Matthew J Ziegelmann; M Ryan Farrell; Laurence A Levine
Journal:  Rev Urol       Date:  2019

Review 2.  Chronic Scrotal Pain.

Authors:  Christopher Wu; Keith Jarvi
Journal:  Curr Urol Rep       Date:  2018-05-31       Impact factor: 3.092

Review 3.  Chronic Scrotal Content Pain: a Review of the Literature and Management Schemes.

Authors:  Paul J Oh; Petar Bajic; Scott D Lundy; Matthew Ziegelmann; Laurence A Levine
Journal:  Curr Urol Rep       Date:  2021-01-15       Impact factor: 3.092

4.  Canadian Urological Association best practice report on chronic scrotal pain.

Authors:  Keith A Jarvi; Christopher Wu; J Curtis Nickel; Trustin Domes; John Grantmyre; Armand Zini
Journal:  Can Urol Assoc J       Date:  2018-02-23       Impact factor: 1.862

Review 5.  Management of Chronic Prostatitis (CP).

Authors:  Nadir Zaidi; Dominique Thomas; Bilal Chughtai
Journal:  Curr Urol Rep       Date:  2018-08-31       Impact factor: 3.092

6.  Changes in whole body pain intensity and widespreadness during urologic chronic pelvic pain syndrome flares-Findings from one site of the MAPP study.

Authors:  Tianlin Xu; H Henry Lai; Ratna Pakpahan; Joel Vetter; Gerald L Andriole; Catherine Bradley; Bruce D Naliboff; Graham A Colditz; Siobhan Sutcliffe
Journal:  Neurourol Urodyn       Date:  2019-09-04       Impact factor: 2.367

7.  Chronic Prostatitis/Chronic Pelvic Pain Syndrome: A Disease or Symptom? Current Perspectives on Diagnosis, Treatment, and Prognosis.

Authors:  Jianzhong Zhang; ChaoZhao Liang; Xuejun Shang; Hongjun Li
Journal:  Am J Mens Health       Date:  2020 Jan-Feb

8.  Clinical Approach to Recurrent Voiding Dysfunction, Dysuria, and Pelvic Pain Persisting for at Least 3 Months.

Authors:  Su Jin Kim; Khae Hawn Kim
Journal:  Int Neurourol J       Date:  2022-09-30       Impact factor: 3.038

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.